Navigation Links
Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses
Date:2/6/2008

ANDOVER, Mass., Feb. 6 /PRNewswire-FirstCall/ -- As it prepares to mark its 10th anniversary of delivering identity and access management solutions to the healthcare industry, Sentillion, the company that created healthcare single sign-on, today announced strong year-end results. In Q4, Sentillion added 10 new customers in North America and the United Kingdom, representing 95,800 new user licenses and brought 17,000 additional users live across its suite of identity and access management products for single sign-on, clinical workstations, user provisioning and virtualized remote access.

In Q4, leading healthcare organizations selected Sentillion IAM solutions for enterprise-wide implementations, including:

-- IASIS Healthcare (Franklin, TN)

-- Southeast Alabama Medical Center (Dothan, AL)

-- Cascade Healthcare Community

-- St. Charles Bend (Bend, Oregon)

-- St. Charles Redmond (Redmond, Oregon)

-- Pioneer Memorial Hospital (Prineville, Oregon)

-- Mt. View District Hospital (Madras, Oregon)

-- University of Alabama at Birmingham Health System (Birmingham, AL)

Underscoring the momentum in its business, Sentillion also reached several other key milestones at the end of 2007, including:

-- Being named the #1 SSO vendor in the KLAS Top 20: 2007 Year-End Report.

As the healthcare industry's leading independent research firm, KLAS

provides a comprehensive summary and assessment of Healthcare

Information Technology (HIT) vendor performance, which is determined

solely by data received through active participation and feedback from

thousands of healthcare organizations.

-- The launch of the Sentillion Channel Partner Program and the signing of

several new channel resellers in the US and UK, including BDS Solutions

(UK), Compudyne (Duluth, MN), iSOFT (UK), Logic Trends (Atlanta), Mile


'/>"/>

SOURCE Sentillion
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sentillion Launches Channel Partner Program for Healthcare-Specific Identity & Access Management Solutions
2. Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firms User Provisioning Magic Quadrant
3. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
4. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
5. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
6. The Female Health Company Announces FDA Acceptance for Review of Its FC2 Premarket Approval Application
7. Thermage, Inc. Announces Fourth Quarter 2007 Results Release Date and Conference Call
8. Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend
9. Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007
10. Genomic Health Announces Fourth Quarter and Year-End 2007 Financial Results and Business Progress and 2008 Financial Guidance
11. AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...NTURA,Fla.,Nov.25/PRNewswire/--DanielTouizer,CEOof...ranteedissuehealthinsurancebenefitprograms,isconce...bermeansnearlyoneinfiveAmericansarewithoutafull-ti...unemploymentratesaredeterminedbytheU-6number,which... Dani e l T ouizer ."Thesestatisticsarealarm...
(Date:11/25/2009)...ease is available in French and Spanish . ,... have provided an early diagnosis of certain ocul...e-related macular degeneration and keratitis, by a...heless, had never before been used for this purpos...image quality in subjects affected by one of these...
(Date:11/25/2009)...ss release is available in French . , , Mont... are about to enter the marketplace, thanks to a n...artnership (Univalor) and Cognitive Sensing Inc. (...n Montreal. , Univalor, which commercializes dis...iliated institutions, and CSI have announced the s...
(Date:11/25/2009)...n fruit fly study may lead to new drugs for people... (HealthDay News) -- Sphingadienes, natural lipid ...ent in treatments for colon cancer, California res...inary, but the study authors pointed out that they...ction against colon cancer. , In the study, Dr....
(Date:11/25/2009)... offer waistline-friendly ways to enjoy festive fe... News) -- If you love the five-week holiday smorga...eady stressing about the added pounds you,ll have ...,s possible, say nutrition experts, to enjoy holid...as you do today. , It,s all about devising a s...
Breaking Medicine News(10 mins):Health News:Cinergy Health Commentary on Health Care for the Unemployed 2Health News:Achieve early diagnosis of ocular pathologies such as keratitis and macular degeneration 2Health News:Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries 2Health News:Natural Soy Component May Help Treat Colon Cancer 2Health News:Holiday Eating Without the Guilt -- or the Pounds 2Health News:Holiday Eating Without the Guilt -- or the Pounds 3
...-Year Growth Since Founded, YARDLEY, Pa., April 1...of corporate performance management solutions, tod... BTI has grown its services,revenue year- over-yea...technology or a,business process solution," said T...
...Civility Mutual, based in,Santa Fe, New Mexico, la...nization to offer education, training and CMEs for...and provides residency directors with the,educatio...gins with effective communication, driven by,respe...
...s April 15, 2008 Elderly patients who use antips...developing pneumonia compared to non-users. This r...ption and decreases gradually thereafter. These fi...f psychosis and behavioral problems associated wit...
... Open Biosystems, Inc.,focused on the commerciali... for drug discovery, today announced the availabil...or multiplexed RNAi screens. This,novel offering a...onal sequencing., (Logo: http://www.newscom.com/...
... /Xinhua-PRNewswire-FirstCall/ -- CNinsure,Inc. CI...kerage company,operating in China, today announced...ship with Minsheng Life Insurance Co., Ltd ("Minsh...d local branch,levels to further promote the busin...
..., 2008 -- Results of a phase IV, open label, head-...e, high-frequency subcutaneous Rebif (interferon b...gs show similar efficacy over 18 to 30 months of c...cal Research and Opinion journal. , The Prospecti...
Other Medicine News:Health News:Breakaway Technologies Celebrates 10 Years in Business 2Health News:New Health Care Company to Offer Training and CMEs on Physician - Patient Communications and Helps Fulfill ACGME Requirements 2Health News:Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens 2Health News:CNinsure Enters Into Strategic Partnership With Minsheng Life Insurance 2Health News:CNinsure Enters Into Strategic Partnership With Minsheng Life Insurance 3Health News:Study shows that high-dose, high-frequency interferon produces no additional benefit 2
(Date:11/24/2009)..., IRVINE,Calif.,Nov.24/PRNewswire-FirstCall/-...yinvasivetreatmentsforaorticdisorders,announcedtod...eedingsin,thepatentinfringementlawsuitbroughtagain...UnitedStatesDistrictCourtinIndianapolis,Indiana. ,...twhiletheUnitedStatesPatentandTrademarkOffice(USPT...
(Date:11/24/2009)..., FREMONT,Calif.,Nov.24/PRNewswire-FirstCall/...theCompanyfileditsPlanofReorganizationandDisclosur...sBankruptcyCourtfortheDistrictofDelaware.Ahearingt...lyscheduledforDecember8,2009,withthehearingontheco..., ThePlancallsfortheCompanytopayallclaimsinfull.Th...
(Date:11/24/2009)..., WOODCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNewsw...U.S.FoodandDrugAdministration(FDA)hasacceptedforre...Aricept®(donepezilHClextendedrelease)tabletsf...(AD).Thisnewhigherdoseformulationcontains23mgofdon...adeliverysystemthatallowsforgradualreleaseofthedru...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Blood flow metabolism mismatch predicts pancreatic tumor aggressiveness 9697 1Blood flow metabolism mismatch predicts pancreatic tumor aggressiveness 9697 2Schwarzeneggers Budget Cuts Force Closure of California AIDS Clearinghouse 55311 1Schwarzeneggers Budget Cuts Force Closure of California AIDS Clearinghouse 55311 2Minorities have poorer results higher rates of inappropriate surgery to prevent stroke 55308 1Minorities have poorer results higher rates of inappropriate surgery to prevent stroke 55308 2
...ll/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; TSX: ...n,endocrine therapy and oncology, today reported t...ruitment for its Phase 2 trial in ovarian cancer,w...one (LHRH) agonist,linked to doxorubicin. The deci...ent was taken following recent first stage data re...
...gual lozenge) developed to be the first sleep aid...hen patients awaken and have difficulty re...ranscept Pharmaceuticals,Inc., a privately-held sp...at it has submitted a New Drug Application (NDA) t...its lead product candidate, Intermezzo(R),(zolpide...
Other Medicine Technology:AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6
BD Visitec Infusion Cannulas
BD Beaver™ Accurate Depth Knives
BD Visitec Irrigating Cystomes
BD Visitec Irrigation and Aspiration Cannulas
Medicine Products: